Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
<,31325302,EC50,"TSC3 showed potent in vitro activity against atovaquone-, dihydroartemisinin-, chloroquine- and mefloquine-resistant P. falciparum lines (EC50 <15 nM).",Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),nM,15,2172,DB01117,Atovaquone
>,31325302,selectivity index,The selectivity index (EC50 cells/EC50Pf W2 line) of TSC3 was >500 in two of three mammalian cell lines.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),,500,2173,DB01117,Atovaquone
,31325302,maximum blood concentration,A single oral dose of TSC3 at 16 mg/kg in healthy mice achieved a mean maximum blood concentration of 1883 ng/mL at 1 h after dosing and an elimination half-life of 48.7 h in groups of five mice.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),[ng] / [ml],1883,2174,DB01117,Atovaquone
,31325302,elimination half-life,A single oral dose of TSC3 at 16 mg/kg in healthy mice achieved a mean maximum blood concentration of 1883 ng/mL at 1 h after dosing and an elimination half-life of 48.7 h in groups of five mice.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),h,48.7,2175,DB01117,Atovaquone
,23927590,z-average diameter,"The ATQ nanosuspension stabilized with Solutol(®) HS 15 (BASF India Ltd, Mumbai, India) and Capryol™ 90 (Gattefosse, Mumbai, India) exhibited a z-average diameter of 371.50 nm and a polydispersity index of 0.19.",Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23927590/),nm,371.50,8911,DB01117,Atovaquone
,23927590,p,"The ATQ nanosuspension stabilized with Solutol(®) HS 15 (BASF India Ltd, Mumbai, India) and Capryol™ 90 (Gattefosse, Mumbai, India) exhibited a z-average diameter of 371.50 nm and a polydispersity index of 0.19.",Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23927590/),,0.19,8912,DB01117,Atovaquone
,16041597,Cmax,"For atovaquone, a Cmax of 1.33-8.33 microg/ml was reached at 2.0-9.3 h after the last dose on day 2.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[μg] / [ml],1.33-8.33,17797,DB01117,Atovaquone
,16041597,V/F,"V/F, CL/F and t(1/2beta) were 6.9-39.5 l/kg, 83-384 ml/h/kg, and 57.8-130.8 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[l] / [kg],6.9-39.5,17798,DB01117,Atovaquone
,16041597,CL/F,"V/F, CL/F and t(1/2beta) were 6.9-39.5 l/kg, 83-384 ml/h/kg, and 57.8-130.8 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],83-384,17799,DB01117,Atovaquone
,16041597,t(1/2beta),"V/F, CL/F and t(1/2beta) were 6.9-39.5 l/kg, 83-384 ml/h/kg, and 57.8-130.8 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,57.8-130.8,17800,DB01117,Atovaquone
,16041597,Cmax,"The Cmax and t(max) values for proguanil versus cycloguanil were 383-918 versus 0-129 ng/ml and 3.3-8.6 versus 3-12 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ng] / [ml],383-918,17801,DB01117,Atovaquone
,16041597,t(max),"The Cmax and t(max) values for proguanil versus cycloguanil were 383-918 versus 0-129 ng/ml and 3.3-8.6 versus 3-12 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ng] / [ml],0-129,17802,DB01117,Atovaquone
,16041597,t(max),"The Cmax and t(max) values for proguanil versus cycloguanil were 383-918 versus 0-129 ng/ml and 3.3-8.6 versus 3-12 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,3.3-8.6,17803,DB01117,Atovaquone
,16041597,t(max),"The Cmax and t(max) values for proguanil versus cycloguanil were 383-918 versus 0-129 ng/ml and 3.3-8.6 versus 3-12 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,3-12,17804,DB01117,Atovaquone
,16041597,V/F,"V/F, CL/F, and t(1/2beta) values for proguanil were 10.7-34.0 l/kg, 431-1,662 ml/h/kg and 11.2-30.3 h.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[l] / [kg],10.7-34.0,17805,DB01117,Atovaquone
,16041597,CL/F,"V/F, CL/F, and t(1/2beta) values for proguanil were 10.7-34.0 l/kg, 431-1,662 ml/h/kg and 11.2-30.3 h.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],"431-1,662",17806,DB01117,Atovaquone
,16041597,t(1/2beta),"V/F, CL/F, and t(1/2beta) values for proguanil were 10.7-34.0 l/kg, 431-1,662 ml/h/kg and 11.2-30.3 h.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,11.2-30.3,17807,DB01117,Atovaquone
,16041597,CL(R-CG),"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],"107.2-1,001",17808,DB01117,Atovaquone
,16041597,t(1/2z),"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],5-95,17809,DB01117,Atovaquone
,16041597,t(1/2z),"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,7.8-20.7,17810,DB01117,Atovaquone
,16041597,metabolic ratios,"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],5-95,17811,DB01117,Atovaquone
,16041597,metabolic ratios,"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,7.8-20.7,17812,DB01117,Atovaquone
,16041597,AUC(,"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],5-95,17813,DB01117,Atovaquone
,16041597,AUC(,"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,7.8-20.7,17814,DB01117,Atovaquone
,19711297,recovery,A single-step protein precipitation technique for plasma extraction of atovaquone achieving mean recovery of 94.17% (CV 8%) without compromising sensitivity (limit of quantitation 50.3 ng/mL) or linearity (50.3 ng/mL-23924.6 ng/mL) is delineated in this paper.,LC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19711297/),%,94.17,18952,DB01117,Atovaquone
,19711297,m/z,Heated nebulizer in negative multiple reaction monitoring mode was employed with transitions m/z 365.2 --> m/z 337.1 and m/z 240.9 --> m/z 185.7 for atovaquone and lapachol respectively in this liquid chromatographic-tandem mass spectrometric method.,LC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19711297/),,240.9,18953,DB01117,Atovaquone
,19711297,m/z,Heated nebulizer in negative multiple reaction monitoring mode was employed with transitions m/z 365.2 --> m/z 337.1 and m/z 240.9 --> m/z 185.7 for atovaquone and lapachol respectively in this liquid chromatographic-tandem mass spectrometric method.,LC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19711297/),,185.7,18954,DB01117,Atovaquone
,12955371,oral clearance (Cl/F),"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),[ml] / [h·kg],313,27954,DB01117,Atovaquone
,12955371,oral clearance (Cl/F),"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),[ml] / [h·kg],1109,27955,DB01117,Atovaquone
,12955371,total apparent volume of distribution (Vd/F),"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),[l] / [kg],13.0,27956,DB01117,Atovaquone
,12955371,total apparent volume of distribution (Vd/F),"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),[l] / [kg],22.9,27957,DB01117,Atovaquone
,12955371,terminal elimination half-life,"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),h,29.1,27958,DB01117,Atovaquone
,12955371,terminal elimination half-life,"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),h,14.3,27959,DB01117,Atovaquone
,33046062,IC50,The compound had been shown to inhibit Plasmodium HDAC with IC50 of 31 nM and human HDAC with IC50 of 3 nM.,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),nM,31,37625,DB01117,Atovaquone
,33046062,IC50,The compound had been shown to inhibit Plasmodium HDAC with IC50 of 31 nM and human HDAC with IC50 of 3 nM.,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),nM,3,37626,DB01117,Atovaquone
,33046062,IC50,The IC50 obtained for P. falciparum in asexual blood-stage assay was 42 nM.,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),nM,42,37627,DB01117,Atovaquone
,33046062,IC50,"The selected compound was also active against gametocytes, indicating a potential for transmission control: IC50 values being 190 nM for male and > 5 µM for female gametocytes.","Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),nM,190,37628,DB01117,Atovaquone
>,33046062,IC50,"The selected compound was also active against gametocytes, indicating a potential for transmission control: IC50 values being 190 nM for male and > 5 µM for female gametocytes.","Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),μM,5,37629,DB01117,Atovaquone
>,33046062,IC50,"FNDR-20123 is a stable candidate in human/mouse/rat liver microsomes (> 75% remaining post 2-h incubation), exhibits low plasma protein binding (57% in humans) with no human Ether-à-go-go-Related Gene (hERG) liability (> 100 µM), and does not inhibit any of the cytochrome P450 (CYP) isoforms tested (IC50 > 25 µM).","Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),μM,25,37630,DB01117,Atovaquone
,33046062,Cmax,The oral pharmacokinetics in rats at 100 mg/kg body weight shows good exposures (Cmax = 1.1 µM) and half-life (T1/2 = 5.5 h).,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),μM,1.1,37631,DB01117,Atovaquone
,33046062,half-life (T1/2,The oral pharmacokinetics in rats at 100 mg/kg body weight shows good exposures (Cmax = 1.1 µM) and half-life (T1/2 = 5.5 h).,"Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046062/),h,5.5,37632,DB01117,Atovaquone
,9534981,peak concentrations,"After a single dose by aerosol, mean peak concentrations of atovaquone averaged 52 microg/mL in plasma and 31 microg/g in lungs of rats infected with P. carinii.","Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9534981/),[μg] / [ml],52,41228,DB01117,Atovaquone
,9534981,peak concentrations,"After a single dose by aerosol, mean peak concentrations of atovaquone averaged 52 microg/mL in plasma and 31 microg/g in lungs of rats infected with P. carinii.","Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9534981/),[μg] / [g],31,41229,DB01117,Atovaquone
,9534981,peak concentrations,"When atovaquone was combined with surfactant, mean peak concentrations of 94 microg/mL in plasma and 51 microg/g in lung were achieved.","Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9534981/),[μg] / [ml],94,41230,DB01117,Atovaquone
,9534981,peak concentrations,"When atovaquone was combined with surfactant, mean peak concentrations of 94 microg/mL in plasma and 51 microg/g in lung were achieved.","Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9534981/),[μg] / [g],51,41231,DB01117,Atovaquone
,21773725,Relative bioavailability,"Relative bioavailability of ATO when loaded in nanoparticles ranged from 52% (for ATO-HPCD NP) to 71% (for ATO-DMCD NP), whereas for the suspension control formulation the bioavailability was only about 30%.",Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21773725/),%,52,45285,DB01117,Atovaquone
,21773725,Relative bioavailability,"Relative bioavailability of ATO when loaded in nanoparticles ranged from 52% (for ATO-HPCD NP) to 71% (for ATO-DMCD NP), whereas for the suspension control formulation the bioavailability was only about 30%.",Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21773725/),%,71,45286,DB01117,Atovaquone
,21773725,bioavailability,"Relative bioavailability of ATO when loaded in nanoparticles ranged from 52% (for ATO-HPCD NP) to 71% (for ATO-DMCD NP), whereas for the suspension control formulation the bioavailability was only about 30%.",Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21773725/),%,30,45287,DB01117,Atovaquone
,11956669,AUC(0-tau),"Four volunteers, with mean CYCLO/PROG AUC(0-tau) of 0.03 (-0.23, 0.09) were classified as poor metaboliser (PM) phenotypes.",Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956669/),,0.03,57414,DB01117,Atovaquone
,11956669,AUC(0-tau)/AUC(0-infinity) ratio,"There was a significant increase in the AUC of PROG at steady state with a PROG AUC(0-tau)/AUC(0-infinity) ratio of 1.38 (1.07, 1.69) in extensive metaboliser (EM) phenotypes.",Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956669/),,1.38,57415,DB01117,Atovaquone
,11956669,AUC ratios,"CYCLO/PROG AUC ratios were significantly lower 0.67 (0.54, 0.81) at steady state than that after the first single dose in EM phenotypes.",Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956669/),,0.67,57416,DB01117,Atovaquone
,1822435,plasma drug elimination half-life,This was well tolerated and the plasma drug elimination half-life was approximately 70h.,566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1822435/),h,70,71516,DB01117,Atovaquone
,8864327,peak plasma concentrations (Cmax),"The mean (+/- s.d.) peak plasma concentrations (Cmax), apparent total clearance (CL/F) and terminal half-life (t1/2) for phenytoin when administered alone were 10.6(1.8) mg 1(-1), 24.3 (7.7) ml min-1 and 25(8) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),mg,10.6,78003,DB01117,Atovaquone
,8864327,apparent total clearance (CL/F),"The mean (+/- s.d.) peak plasma concentrations (Cmax), apparent total clearance (CL/F) and terminal half-life (t1/2) for phenytoin when administered alone were 10.6(1.8) mg 1(-1), 24.3 (7.7) ml min-1 and 25(8) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),[ml] / [min],24.3,78004,DB01117,Atovaquone
,8864327,terminal half-life (t1/2),"The mean (+/- s.d.) peak plasma concentrations (Cmax), apparent total clearance (CL/F) and terminal half-life (t1/2) for phenytoin when administered alone were 10.6(1.8) mg 1(-1), 24.3 (7.7) ml min-1 and 25(8) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),h,25,78005,DB01117,Atovaquone
,8864327,Cmax,"When administered together with atovaquone, phenytoin Cmax, CL/F and t1/2,z were 10.9 (2.0) mg 1(-1), 23.8 ml min-1 and 24(6) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),mg,10.9,78006,DB01117,Atovaquone
,8864327,CL/F,"When administered together with atovaquone, phenytoin Cmax, CL/F and t1/2,z were 10.9 (2.0) mg 1(-1), 23.8 ml min-1 and 24(6) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),[ml] / [min],23.8,78007,DB01117,Atovaquone
,8864327,"t1/2,z","When administered together with atovaquone, phenytoin Cmax, CL/F and t1/2,z were 10.9 (2.0) mg 1(-1), 23.8 ml min-1 and 24(6) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),h,24,78008,DB01117,Atovaquone
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],3.28,80932,DB01117,Atovaquone
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],8.49,80933,DB01117,Atovaquone
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],9.13,80934,DB01117,Atovaquone
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,345,80935,DB01117,Atovaquone
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,383,80936,DB01117,Atovaquone
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,428,80937,DB01117,Atovaquone
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,72.9,80938,DB01117,Atovaquone
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,31.3,80939,DB01117,Atovaquone
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,32.5,80940,DB01117,Atovaquone
,22052893,area under the curve,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [d·ml],423,81603,DB01117,Atovaquone
,22052893,area under the curve,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [d·ml],199,81604,DB01117,Atovaquone
,22052893,area under the curve,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [d·ml],1903,81605,DB01117,Atovaquone
,22052893,peak concentration,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [ml],165,81606,DB01117,Atovaquone
,22052893,peak concentration,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [ml],81,81607,DB01117,Atovaquone
,22052893,peak concentration,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [ml],594,81608,DB01117,Atovaquone
,22052893,Elimination half-life,"Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),d,2.4,81609,DB01117,Atovaquone
,22052893,Elimination half-life,"Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),d,2.0,81610,DB01117,Atovaquone
,22052893,Elimination half-life,"Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),d,3.3,81611,DB01117,Atovaquone
,22052893,Elimination half-life,"Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),d,4.1,81612,DB01117,Atovaquone
,30613327,IC50 (concentration of drug required to achieve half maximal growth suppression),"The most potent compounds display no cross-resistance with multidrug resistant parasite strains (W2) compared to drug sensitive strains (3D7), with IC50 (concentration of drug required to achieve half maximal growth suppression) values in the range of 15-33 nM.",Potent Antimalarial 2-Pyrazolyl Quinolone bc 1 (Qi) Inhibitors with Improved Drug-like Properties. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30613327/),nM,15-33,85911,DB01117,Atovaquone
,9279980,CL/F,"The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6).",Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279980/),[l] / [h·kg],1.25,98935,DB01117,Atovaquone
,9279980,CL/F,"The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6).",Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279980/),[l] / [h·kg],0.95,98936,DB01117,Atovaquone
,9279980,t1/2,"The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6).",Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279980/),h,14.2,98937,DB01117,Atovaquone
,9279980,t1/2,"The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6).",Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279980/),h,13.6,98938,DB01117,Atovaquone
,31880260,PDI,"The prepared nanosuspension had a mean particle size of 865 nm ± 5%, PDI of 0.261 ± 3%, and zeta potential of -1.79 ± 5 mV.",Development of Atovaquone Nanosuspension: Quality by Design Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880260/),%,0.261,106820,DB01117,Atovaquone
,31880260,zeta potential,"The prepared nanosuspension had a mean particle size of 865 nm ± 5%, PDI of 0.261 ± 3%, and zeta potential of -1.79 ± 5 mV.",Development of Atovaquone Nanosuspension: Quality by Design Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880260/),m,-1.79,106821,DB01117,Atovaquone
,8951190,CLo,"According to the mean weight of each population, the final population estimates of CLo in Blacks, Orientals and Malays who are 'extensive' metabolizers were 54.0, 61.5 and 64.3 l h-1, respectively.",Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951190/),[l] / [h],54.0,113316,DB01117,Atovaquone
,8951190,CLo,"According to the mean weight of each population, the final population estimates of CLo in Blacks, Orientals and Malays who are 'extensive' metabolizers were 54.0, 61.5 and 64.3 l h-1, respectively.",Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951190/),[l] / [h],61.5,113317,DB01117,Atovaquone
,8951190,CLo,"According to the mean weight of each population, the final population estimates of CLo in Blacks, Orientals and Malays who are 'extensive' metabolizers were 54.0, 61.5 and 64.3 l h-1, respectively.",Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951190/),[l] / [h],64.3,113318,DB01117,Atovaquone
>,26797214,C avg,"Only 5 of 10 subjects receiving EFV-based cART plus atovaquone 750 mg BID had an atovaquone C avg>15 µg/mL, which has previously been associated with successful treatment of Pneumocystis jirovecipneumonia.",Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26797214/),[μg] / [ml],15,132262,DB01117,Atovaquone
>,26797214,C avg,"Nine of 10 subjects not receiving cART, 8 of 10 subjects receiving ATV/r, and 2 of 10 subjects receiving EFV in combination with atovaquone 750 mg BID achieved an atovaquone C avg>18.5 µg/mL, a concentration that has previously been associated with successful treatment of Toxoplasmaencephalitis (TE).",Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26797214/),[μg] / [ml],18.5,132263,DB01117,Atovaquone
,2010637,maximum plasma concentration,"With the largest dosage tested (3000 mg) the following pharmacokinetic measures were achieved: maximum plasma concentration, 39 micrograms/ml; time to maximum plasma concentration, 8.0 h; area under plasma concentration-time curve at steady state, 1088 h.micrograms/ml; plasma half-life, 51 h; and total plasma clearance, 4.09 l/h.","Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2010637/),[μg] / [ml],39,133734,DB01117,Atovaquone
,2010637,time to maximum plasma concentration,"With the largest dosage tested (3000 mg) the following pharmacokinetic measures were achieved: maximum plasma concentration, 39 micrograms/ml; time to maximum plasma concentration, 8.0 h; area under plasma concentration-time curve at steady state, 1088 h.micrograms/ml; plasma half-life, 51 h; and total plasma clearance, 4.09 l/h.","Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2010637/),h,8.0,133735,DB01117,Atovaquone
,2010637,area under plasma concentration-time curve at steady state,"With the largest dosage tested (3000 mg) the following pharmacokinetic measures were achieved: maximum plasma concentration, 39 micrograms/ml; time to maximum plasma concentration, 8.0 h; area under plasma concentration-time curve at steady state, 1088 h.micrograms/ml; plasma half-life, 51 h; and total plasma clearance, 4.09 l/h.","Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2010637/),[h·μg] / [ml],1088,133736,DB01117,Atovaquone
,2010637,plasma half-life,"With the largest dosage tested (3000 mg) the following pharmacokinetic measures were achieved: maximum plasma concentration, 39 micrograms/ml; time to maximum plasma concentration, 8.0 h; area under plasma concentration-time curve at steady state, 1088 h.micrograms/ml; plasma half-life, 51 h; and total plasma clearance, 4.09 l/h.","Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2010637/),h,51,133737,DB01117,Atovaquone
,2010637,total plasma clearance,"With the largest dosage tested (3000 mg) the following pharmacokinetic measures were achieved: maximum plasma concentration, 39 micrograms/ml; time to maximum plasma concentration, 8.0 h; area under plasma concentration-time curve at steady state, 1088 h.micrograms/ml; plasma half-life, 51 h; and total plasma clearance, 4.09 l/h.","Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2010637/),[l] / [h],4.09,133738,DB01117,Atovaquone
greater,9624466,steady-state concentration,"Dosages of 30 mg/kg/day were adequate to achieve an average steady-state concentration of greater than 15 micrograms/ml in children ages 1 to 3 months and 2 to 12 years, but a dosage of 45 mg/kg/day was needed to reach this concentration in infants 3 to 24 months of age.",Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624466/),[μg] / [ml],15,138754,DB01117,Atovaquone
,11459198,apparent Ki,"Using uptake of 3H-vinblastine in L-MDR1 cells, atovaquone was shown to inhibit P-glycoprotein with an apparent Ki of 95.6 microM.",The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459198/),μM,95.6,159828,DB01117,Atovaquone
,9764334,Para,"Parasite and fever clearance times were 47 h (range 8-75) and 50 h (range 7-111), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,47,165773,DB01117,Atovaquone
,9764334,clearance times,"Parasite and fever clearance times were 47 h (range 8-75) and 50 h (range 7-111), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,50,165774,DB01117,Atovaquone
,9764334,time to peak concentrations,"Atovaquone and proguanil were rapidly absorbed, with median time to peak concentrations of 6 h (range 6-24) and 6 h (range 6-12), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,6,165775,DB01117,Atovaquone
,9764334,time to peak concentrations,"Atovaquone and proguanil were rapidly absorbed, with median time to peak concentrations of 6 h (range 6-24) and 6 h (range 6-12), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,6,165776,DB01117,Atovaquone
,9764334,peak plasma concentration,Mean peak plasma concentration of atovaquone on day 3 was 5.1 micrograms/mL (SD = 2.1).,Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[μg] / [ml],5.1,165777,DB01117,Atovaquone
,9764334,peak plasma concentration,The day 3 mean peak plasma concentration of proguanil was 306 ng/mL (SD = 108) compared with 44.3 ng/mL (SD = 27.3) for cycloguanil.,Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[ng] / [ml],306,165778,DB01117,Atovaquone
,9764334,peak plasma concentration,The day 3 mean peak plasma concentration of proguanil was 306 ng/mL (SD = 108) compared with 44.3 ng/mL (SD = 27.3) for cycloguanil.,Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[ng] / [ml],44.3,165779,DB01117,Atovaquone
,9764334,AUC (area under plasma concentration-time curve),"Mean values for the AUC (area under plasma concentration-time curve) were 161.8 micrograms/mL.h (SD = 126.9) for atovaquone, 4646 ng/mL.h (SD = 1226) for proguanil, and 787 ng/mL.h (SD = 397) for cycloguanil.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[μg] / [h·ml],161.8,165780,DB01117,Atovaquone
,9764334,AUC (area under plasma concentration-time curve),"Mean values for the AUC (area under plasma concentration-time curve) were 161.8 micrograms/mL.h (SD = 126.9) for atovaquone, 4646 ng/mL.h (SD = 1226) for proguanil, and 787 ng/mL.h (SD = 397) for cycloguanil.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[ng] / [h·ml],4646,165781,DB01117,Atovaquone
,9764334,AUC (area under plasma concentration-time curve),"Mean values for the AUC (area under plasma concentration-time curve) were 161.8 micrograms/mL.h (SD = 126.9) for atovaquone, 4646 ng/mL.h (SD = 1226) for proguanil, and 787 ng/mL.h (SD = 397) for cycloguanil.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[ng] / [h·ml],787,165782,DB01117,Atovaquone
,9764334,Terminal elimination half-lives,"Terminal elimination half-lives of atovaquone, proguanil and cycloguanil were estimated as 31.8 h (SD = 8.9), 14.9 h (SD = 3.3) and 14.6 h (SD = 2.6), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,31.8,165783,DB01117,Atovaquone
,9764334,Terminal elimination half-lives,"Terminal elimination half-lives of atovaquone, proguanil and cycloguanil were estimated as 31.8 h (SD = 8.9), 14.9 h (SD = 3.3) and 14.6 h (SD = 2.6), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,14.9,165784,DB01117,Atovaquone
,9764334,Terminal elimination half-lives,"Terminal elimination half-lives of atovaquone, proguanil and cycloguanil were estimated as 31.8 h (SD = 8.9), 14.9 h (SD = 3.3) and 14.6 h (SD = 2.6), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,14.6,165785,DB01117,Atovaquone
,8549029,area under the zidovudine concentration-time curve (AUC),Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[h·μg] / [ml],1.82,168099,DB01117,Atovaquone
,8549029,area under the zidovudine concentration-time curve (AUC),Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[h·μg] / [ml],2.39,168100,DB01117,Atovaquone
,8549029,oral clearance,Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[ml] / [min],2029,168101,DB01117,Atovaquone
,8549029,oral clearance,Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[ml] / [min],1512,168102,DB01117,Atovaquone
,8549029,AUC,"In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05).",Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[h·μg] / [ml],7.31,168103,DB01117,Atovaquone
,8549029,AUC,"In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05).",Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[h·μg] / [ml],6.89,168104,DB01117,Atovaquone
,8549029,ratio of AUC,"In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05).",Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),,4.48,168105,DB01117,Atovaquone
,8549029,ratio of AUC,"In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05).",Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),,3.12,168106,DB01117,Atovaquone
,8549029,maximum concentration,The maximum concentration of zidovudine-glucuronide was significantly lowered by atovaquone (5.7 +/- 1.5 versus 4.57 +/- 0.97 micrograms/ml; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[μg] / [ml],5.7,168107,DB01117,Atovaquone
,8549029,maximum concentration,The maximum concentration of zidovudine-glucuronide was significantly lowered by atovaquone (5.7 +/- 1.5 versus 4.57 +/- 0.97 micrograms/ml; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[μg] / [ml],4.57,168108,DB01117,Atovaquone
,21612571,fluxes,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],12.89,181642,DB01117,Atovaquone
,21612571,fluxes,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],5.88,181643,DB01117,Atovaquone
,21612571,plasma concentrations,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [ml],1.4,181644,DB01117,Atovaquone
,21612571,plasma concentrations,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[ng] / [ml],200,181645,DB01117,Atovaquone
,21612571,fluxes,"However, in the second study, the fluxes of AT and PR increased to 50.92 ± 20.8 and 12.01 ± 1.5 µg cm(-2) h(-1) respectively, and pharmacokinetic calculations indicated that therapeutic plasma concentrations are attainable for pediatric application.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],50.92,181646,DB01117,Atovaquone
,21612571,fluxes,"However, in the second study, the fluxes of AT and PR increased to 50.92 ± 20.8 and 12.01 ± 1.5 µg cm(-2) h(-1) respectively, and pharmacokinetic calculations indicated that therapeutic plasma concentrations are attainable for pediatric application.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],12.01,181647,DB01117,Atovaquone
,25047305,elimination half-lives,"AS and DHA showed mean elimination half-lives of 0.17 hours and 1.30 hours, respectively.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),h,0.17,188992,DB01117,Atovaquone
,25047305,elimination half-lives,"AS and DHA showed mean elimination half-lives of 0.17 hours and 1.30 hours, respectively.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),h,1.30,188993,DB01117,Atovaquone
,25047305,peak concentration (Cmax),"The high mean peak concentration (Cmax) of AS was shown to be 28,558 ng/mL while the Cmax of DHA was determined to be 2,932 ng/mL.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[ng] / [ml],"28,558",188994,DB01117,Atovaquone
,25047305,Cmax,"The high mean peak concentration (Cmax) of AS was shown to be 28,558 ng/mL while the Cmax of DHA was determined to be 2,932 ng/mL.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[ng] / [ml],"2,932",188995,DB01117,Atovaquone
,25047305,Cmax,"For example, Cmax values of AS were calculated to range from 3,362 to 55,873 ng/mL, and the Cmax value of DHA was noted to vary from 1,493 to 5,569 ng/mL.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[ng] / [ml],"3,362 to 55,873",188996,DB01117,Atovaquone
,25047305,Cmax,"For example, Cmax values of AS were calculated to range from 3,362 to 55,873 ng/mL, and the Cmax value of DHA was noted to vary from 1,493 to 5,569 ng/mL.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[ng] / [ml],"1,493 to 5,569",188997,DB01117,Atovaquone
,25047305,area under the curve (AUC),"The mean area under the curve (AUC) of AS was shown to be approximately half that of DHA (1,878 ng · h/mL vs 3,543 ng · h/mL).",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[h·ng] / [ml],"1,878",188998,DB01117,Atovaquone
,25047305,area under the curve (AUC),"The mean area under the curve (AUC) of AS was shown to be approximately half that of DHA (1,878 ng · h/mL vs 3,543 ng · h/mL).",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[h·ng] / [ml],"3,543",188999,DB01117,Atovaquone
,28651341,Cmin,The median Cmin (IQR) was 11.3 μg/mL (6.2-27.8) and the median Cmax was 13.4 μg/mL (6.0-28.3).,Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],11.3,207131,DB01117,Atovaquone
,28651341,Cmax,The median Cmin (IQR) was 11.3 μg/mL (6.2-27.8) and the median Cmax was 13.4 μg/mL (6.0-28.3).,Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],13.4,207132,DB01117,Atovaquone
<,28651341,Cmin,"Nineteen of the 33 (58%) patients had Cmin <15 μg/mL, a threshold associated with a low rate of clinical response in PCP treatment.",Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],15,207133,DB01117,Atovaquone
,12556158,plasma half-lives,"Published pharmacokinetic data indicate that after treatment of patients with therapeutic doses of atovaquone/proguanil hydrochloride (Malarone, GlaxoSmithKline Research Triangle Park, NC), the plasma half-lives of these drugs are 70h and 15h, respectively.",Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12556158/),h,70,210620,DB01117,Atovaquone
,12556158,plasma half-lives,"Published pharmacokinetic data indicate that after treatment of patients with therapeutic doses of atovaquone/proguanil hydrochloride (Malarone, GlaxoSmithKline Research Triangle Park, NC), the plasma half-lives of these drugs are 70h and 15h, respectively.",Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12556158/),h,15,210621,DB01117,Atovaquone
,9793589,AUC0-24,The mean AUC0-24 after the fasting dose was 43.4 micrograms.h/mL.,Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793589/),[h·μg] / [ml],43.4,210854,DB01117,Atovaquone
,9793589,AUC0-24,The mean AUC0-24 values with breakfast (103.8 micrograms.h/mL) and Sustacal Plus (118.8 micrograms.h/mL) were significantly greater compared with fasting (p < 0.0001).,Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793589/),[h·μg] / [ml],103.8,210855,DB01117,Atovaquone
,9793589,AUC0-24,The mean AUC0-24 values with breakfast (103.8 micrograms.h/mL) and Sustacal Plus (118.8 micrograms.h/mL) were significantly greater compared with fasting (p < 0.0001).,Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793589/),[h·μg] / [ml],118.8,210856,DB01117,Atovaquone
,10492061,maximum plasma concentrations,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[μg] / [ml],13.02,237891,DB01117,Atovaquone
,10492061,maximum plasma concentrations,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[ng] / [ml],742,237892,DB01117,Atovaquone
,10492061,elimination half-lives,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),h,42.2,237893,DB01117,Atovaquone
,10492061,elimination half-lives,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),h,14.4,237894,DB01117,Atovaquone
,10492061,oral plasma clearance,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[ml] / [h·kg],90,237895,DB01117,Atovaquone
,10492061,oral plasma clearance,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[ml] / [h·kg],710,237896,DB01117,Atovaquone
,10492061,apparent volumes of distribution,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[1] / [kg],4.9,237897,DB01117,Atovaquone
,10492061,apparent volumes of distribution,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[1] / [kg],14.5,237898,DB01117,Atovaquone
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],6.7,242970,DB01117,Atovaquone
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],11.3,242971,DB01117,Atovaquone
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],9.9,242972,DB01117,Atovaquone
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],12.5,242973,DB01117,Atovaquone
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],9.7,242974,DB01117,Atovaquone
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],13.6,242975,DB01117,Atovaquone
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],21.1,242976,DB01117,Atovaquone
less,10610011,steady-state concentrations,"Average steady-state concentrations were less than 10 microg/ml in 21% and more than 15 microg/ml in 36% of patients at 1000 mg/day with food; at 750 mg twice/day, all five patients had levels above 15 microg/ml.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],10,242977,DB01117,Atovaquone
more,10610011,steady-state concentrations,"Average steady-state concentrations were less than 10 microg/ml in 21% and more than 15 microg/ml in 36% of patients at 1000 mg/day with food; at 750 mg twice/day, all five patients had levels above 15 microg/ml.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],15,242978,DB01117,Atovaquone
,10424325,area under the atovaquone plasma concentration-time curve calculated from 0 to 24 h after the last dose (AUC0->24h),The geometric mean of the area under the atovaquone plasma concentration-time curve calculated from 0 to 24 h after the last dose (AUC0->24h) was 180 microg x ml(-1) h following administration of atovaquone alone and 193 microg x ml(-1) h following atovaquone with proguanil.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),[h·μg] / [ml],180,246433,DB01117,Atovaquone
,10424325,area under the atovaquone plasma concentration-time curve calculated from 0 to 24 h after the last dose (AUC0->24h),The geometric mean of the area under the atovaquone plasma concentration-time curve calculated from 0 to 24 h after the last dose (AUC0->24h) was 180 microg x ml(-1) h following administration of atovaquone alone and 193 microg x ml(-1) h following atovaquone with proguanil.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),[h·μg] / [ml],193,246434,DB01117,Atovaquone
,10424325,AUC0->24h,The geometric mean AUC0->24h for proguanil was 6296 ng x ml(-1) x h after proguanil alone and 5819 ng x ml(-1) x h following proguanil with atovaquone.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),[h·ng] / [ml],6296,246435,DB01117,Atovaquone
,10424325,AUC0->24h,The geometric mean AUC0->24h for proguanil was 6296 ng x ml(-1) x h after proguanil alone and 5819 ng x ml(-1) x h following proguanil with atovaquone.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),[h·ng] / [ml],5819,246436,DB01117,Atovaquone
,10424325,elimination half-life (t1/2),The geometric mean elimination half-life (t1/2) of atovaquone was 57.1 h when given alone and 59.0 h when administered together with proguanil.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),h,57.1,246437,DB01117,Atovaquone
,10424325,elimination half-life (t1/2),The geometric mean elimination half-life (t1/2) of atovaquone was 57.1 h when given alone and 59.0 h when administered together with proguanil.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),h,59.0,246438,DB01117,Atovaquone
,10424325,t1/2,The corresponding geometric mean values of t1/2 for proguanil were 13.7 h and 14.5 h.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),h,13.7,246439,DB01117,Atovaquone
,10424325,t1/2,The corresponding geometric mean values of t1/2 for proguanil were 13.7 h and 14.5 h.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),h,14.5,246440,DB01117,Atovaquone
,12659609,maximum serum concentration,Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.,Toxicity related to chloroquine treatment of resistant vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659609/),[μg] / [l],902,256908,DB01117,Atovaquone
,8851570,steady-state concentrations,"All patients who received 1,000 mg twice daily with food achieved target steady-state concentrations in plasma of 15 to 25 micrograms/ml.",Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851570/),[μg] / [ml],15 to 25,257655,DB01117,Atovaquone
less,26969110,solubility,"However, Atovaquone is a highly lipophilic drug having poor aqueous solubility (less than 0.2 μg/ml) thus reducing its oral bioavailability.",Bioavailability enhancement of atovaquone using hot melt extrusion technology. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26969110/),[μg] / [ml],0.2,259354,DB01117,Atovaquone
,16552504,oral clearance (CI/F),"For DHA the median [90% range] estimate of oral clearance (CI/F) was 4.0 [0.8-20.7] l hour(-1) kg(-1), total apparent volume of distribution (Vd/f) was 3.4 [0.9-60.7] l/kg, and terminal elimination half-life was 1.0 [0.6-2.4] h.",Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16552504/),[l] / [hour·kg],4.0,259475,DB01117,Atovaquone
,16552504,total apparent volume of distribution (Vd/f),"For DHA the median [90% range] estimate of oral clearance (CI/F) was 4.0 [0.8-20.7] l hour(-1) kg(-1), total apparent volume of distribution (Vd/f) was 3.4 [0.9-60.7] l/kg, and terminal elimination half-life was 1.0 [0.6-2.4] h.",Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16552504/),[l] / [kg],3.4,259476,DB01117,Atovaquone
,16552504,terminal elimination half-life,"For DHA the median [90% range] estimate of oral clearance (CI/F) was 4.0 [0.8-20.7] l hour(-1) kg(-1), total apparent volume of distribution (Vd/f) was 3.4 [0.9-60.7] l/kg, and terminal elimination half-life was 1.0 [0.6-2.4] h.",Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16552504/),h,1.0,259477,DB01117,Atovaquone
less,21914160,half-life,"Intravenous AS is associated with high initial AS concentrations which subsequently decline rapidly, with typical AS half-life estimates of less than 15 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,15,260913,DB01117,Atovaquone
,21914160,clearance,"AS clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [h·kg],2 - 3,260914,DB01117,Atovaquone
,21914160,volume,"AS clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [kg],0.1 - 0.3,260915,DB01117,Atovaquone
,21914160,half-life,"DHA concentrations peak within 25 minutes post-dose, and DHA is eliminated with a half-life of 30 - 60 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,30 - 60,260916,DB01117,Atovaquone
,21914160,clearance,"DHA clearance and volume average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [h·kg],0.5 - 1.5,260917,DB01117,Atovaquone
,21914160,volume,"DHA clearance and volume average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [kg],0.5 - 1.0,260918,DB01117,Atovaquone
>,21914160,bioavailability,"Compared to IV administration, IM administration produces lower peaks, longer half-life values, and higher volumes of distribution for AS, as well as delayed peaks for DHA; other parameters are generally similar due to the high bioavailability, assessed by exposure to DHA, associated with IM AS administration (> 86%).","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),%,86,260919,DB01117,Atovaquone
>,21914160,bioavailability,Similarly high bioavailability of DHA (> 80%) is associated with oral administration.,"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),%,80,260920,DB01117,Atovaquone
,21914160,half-life,"Following oral AS, peak AS concentrations (Cmax) are achieved within one hour, and AS is eliminated with a half-life of 20 - 45 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,20 - 45,260921,DB01117,Atovaquone
,21914160,half-life,DHA Cmax values are observed within two hours post-dose; DHA half-life values average 0.5 - 1.5 hours.,"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),h,0.5 - 1.5,260922,DB01117,Atovaquone
